Abstract:Metabolic syndrome is weakly and non significantly associated with prostate cancer risk, but associations vary with geography. Among single components of the syndrome, hypertension and higher waist circumference are significantly associated with increased risk of prostate cancer.
“…Some reviews that have linked obesity with prostate cancer have indicated that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. [9] A similar finding was documented in a study among healthy Koreans that showed higher waist circumference and fasting plasma glucose level were significantly associated with lower PSA (low risk for PCa) but not with MetS, [10] while in another meta analysis by Esposito et al, [11] found higher waist circumference to be significantly associated with increased levels of PSA. Previous studies demonstrated that men with type 2 diabetes mellitus consistently had significantly lower serum prostate-specific antigen levels than healthy men.…”
Section: Introductionsupporting
confidence: 68%
“…Most of the reviews and meta analysis are as varied as always on the complicity of metabolic syndrome in prostate cancer pathogenesis. A meta analysis by Esposito K. et al, [11] showed that metabolic syndrome is weakly and non significantly associated with prostate cancer and this varies with geography, race and/or ethnicity while Gacci M. et al, [7] and Rhee H. et al, [8] in a more recent meta analysis revealed that metabolic syndrome may not be involved directly in the pathogenesis of prostate cancer rather it is associated with severity of the tumour including its aggressiveness, worse outcome and biochemical recurrence on the background hormones dysregulation. Although the relationship between metabolic syndrome and prostate cancer is inconclusive and more often than not confusing, the individual components of metabolic syndrome maintain a Section: Medicine rather definitive heterogeneous relationship with serum total PSA.…”
Section: Discussionmentioning
confidence: 99%
“…[12] Among all the individual metabolic components, hypertension is the most consistently associated with increased PSA levels hence higher risk of PCa. Several meta analyses, [10,11,13] have revealed that hypertension singularly or in collaboration with other components, is associated with an increased risk of prostate cancer. In another study, [4] it was observed that there was an inverse relationship between the body mass index, HDL, and FBG with the serum PSA level.…”
Background: Previous studies demonstrated that individual components of metabolic syndrome affect prostate-specific antigen levels negatively or otherwise in men. However the influence of metabolic syndrome on serum PSA is inconclusive and unknown in this community setting. The aim of the study was therefore to investigate the relationships between metabolic syndrome and its components with serum PSA levels. Methods: The survey was a cross sectional conducted in a semi urban community in Jigawa state, Northern Nigeria. The subjects comprises 352 healthy men. Simple convenient sampling technique was used to recruit consenting adults. The study protocols was approved by the local health authority. All persons with symptoms of prostitis or urinary obstruction were excluded. The data obtained included personal and anthropometric, while lipids, glucose, TSH and serum PSA were measured using ELISA technique. The IDF criteria of metabolic syndrome were used. Serum PSA levels of >5.0 ng/ml is considered as risk of prostate cancer. The data was analysed using SPSS 23 version. Results: A total of 352 adults were screened with mean age 37.8(9.4) years and mean serum total PSA of 2.73(4.10)ng/ml. The proportion found with total serum PSA >5.0ng/ml was 10.8% (38/350). Metabolic syndrome was found in 6.8% (24/350) of the study subjects and had serum total PSA of 1.8(1.1) as against 2.9(4.2) in those without metabolic syndrome p<0.05. The Weight, WC, BMI and TG levels were higher in those with raised serum PSA than in those with normal serum PSA values; 64.4(12.5)/61.9(9.7)kg, 83.6(12.9)/78.8(9.8)cm, 22.8(3.5)/22.0(3.8) and 1.08(0.67)/0.89(0.52)mmol/L respectively >0.05. Logistic regression showed positive linear relationship between central adiposity with total serum PSA. p<0.05. Conclusion: It is concluded that the risk of prostate cancer is inversely related to the metabolic syndrome and positively associated with central adiposity.
“…Some reviews that have linked obesity with prostate cancer have indicated that obesity may not necessarily increase the risk of prostate cancer, but may promote it once established. [9] A similar finding was documented in a study among healthy Koreans that showed higher waist circumference and fasting plasma glucose level were significantly associated with lower PSA (low risk for PCa) but not with MetS, [10] while in another meta analysis by Esposito et al, [11] found higher waist circumference to be significantly associated with increased levels of PSA. Previous studies demonstrated that men with type 2 diabetes mellitus consistently had significantly lower serum prostate-specific antigen levels than healthy men.…”
Section: Introductionsupporting
confidence: 68%
“…Most of the reviews and meta analysis are as varied as always on the complicity of metabolic syndrome in prostate cancer pathogenesis. A meta analysis by Esposito K. et al, [11] showed that metabolic syndrome is weakly and non significantly associated with prostate cancer and this varies with geography, race and/or ethnicity while Gacci M. et al, [7] and Rhee H. et al, [8] in a more recent meta analysis revealed that metabolic syndrome may not be involved directly in the pathogenesis of prostate cancer rather it is associated with severity of the tumour including its aggressiveness, worse outcome and biochemical recurrence on the background hormones dysregulation. Although the relationship between metabolic syndrome and prostate cancer is inconclusive and more often than not confusing, the individual components of metabolic syndrome maintain a Section: Medicine rather definitive heterogeneous relationship with serum total PSA.…”
Section: Discussionmentioning
confidence: 99%
“…[12] Among all the individual metabolic components, hypertension is the most consistently associated with increased PSA levels hence higher risk of PCa. Several meta analyses, [10,11,13] have revealed that hypertension singularly or in collaboration with other components, is associated with an increased risk of prostate cancer. In another study, [4] it was observed that there was an inverse relationship between the body mass index, HDL, and FBG with the serum PSA level.…”
Background: Previous studies demonstrated that individual components of metabolic syndrome affect prostate-specific antigen levels negatively or otherwise in men. However the influence of metabolic syndrome on serum PSA is inconclusive and unknown in this community setting. The aim of the study was therefore to investigate the relationships between metabolic syndrome and its components with serum PSA levels. Methods: The survey was a cross sectional conducted in a semi urban community in Jigawa state, Northern Nigeria. The subjects comprises 352 healthy men. Simple convenient sampling technique was used to recruit consenting adults. The study protocols was approved by the local health authority. All persons with symptoms of prostitis or urinary obstruction were excluded. The data obtained included personal and anthropometric, while lipids, glucose, TSH and serum PSA were measured using ELISA technique. The IDF criteria of metabolic syndrome were used. Serum PSA levels of >5.0 ng/ml is considered as risk of prostate cancer. The data was analysed using SPSS 23 version. Results: A total of 352 adults were screened with mean age 37.8(9.4) years and mean serum total PSA of 2.73(4.10)ng/ml. The proportion found with total serum PSA >5.0ng/ml was 10.8% (38/350). Metabolic syndrome was found in 6.8% (24/350) of the study subjects and had serum total PSA of 1.8(1.1) as against 2.9(4.2) in those without metabolic syndrome p<0.05. The Weight, WC, BMI and TG levels were higher in those with raised serum PSA than in those with normal serum PSA values; 64.4(12.5)/61.9(9.7)kg, 83.6(12.9)/78.8(9.8)cm, 22.8(3.5)/22.0(3.8) and 1.08(0.67)/0.89(0.52)mmol/L respectively >0.05. Logistic regression showed positive linear relationship between central adiposity with total serum PSA. p<0.05. Conclusion: It is concluded that the risk of prostate cancer is inversely related to the metabolic syndrome and positively associated with central adiposity.
“…Metabolic syndrome has been linked with an increased risk of PCa [5], but there is insufficient evidence to recommend lifestyle changes or a modified diet to lower this risk. In hypogonadal men, testosterone therapy is not associated with an increased PCa risk [6].…”
“…Metabolic syndrome is linked with prostate cancer risk and varies with geography (Esposito et al, 2013). The pervasiveness of metabolic syndrome is rising worldwide and allied with an augmented risk of the assertiveness and succession of prostate cancer (Xiang et al, 2013).…”
Of the total 125 subjects enrolled in our present study, 25 cases were of PCa and 100 were healthy controls. The mean value of fasting plasma glucose was 95.5 mg/dl in cases of prostatic carcinoma and the mean value of fasting plasma insulin was 5.78 µU/ml (p value: 0.0001*). The fasting insulin levels µU/ml were categorized into the different ranges starting from ≤2.75, >2.75 to ≤4.10, >4.10 to ≤6.10, >6.10µU/ml. The maximum number of cases of prostatic carcinoma of fasting insulin levels falls in range of >6.10µU/ml. The highest insulin levels (>6.10µU/ml) were seen to be associated with an 2.55 fold risk of prostatic carcinoma when compared with fasting insulin levels of (<2.75 µU/ml). Conclusions: Elevated fasting levels of serum insulin appear to be associated with a higher risk of prostate cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.